Inventor · disambiguated record
Matthew Michael Kreilein
Also filed as: KREILEIN MATTHEW M · KREILEIN MATTHEW MICHAEL
18 granted patents·81 citations·filing 2010–2019
93Inventor score
Top patents by PatentIndex Score
18 records- 0193US10316016B2Compositions comprising an inhibitor of lysine specific demethylase-1CELGENE QUANTICEL RES INC·Filed 2018·Granted Jun 11, 2019·4 cites·8 claims
- 0292US10047069B2Compositions comprising an inhibitor of lysine specific demethylase-1CELGENE QUANTICEL RES INC·Filed 2017·Granted Aug 14, 2018·4 cites·3 claims
- 0392US9359364B2Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-oneSIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·10 cites·28 claims
- 0491US9067912B2Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dioneCELGENE CORP·Filed 2014·Granted Jun 30, 2015·5 cites·42 claims
- 0591US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 0690US10703739B2Compositions comprising an inhibitor of lysine specific demethylase-1CELGENE QUANTICEL RES INC·Filed 2019·Granted Jul 7, 2020·2 cites·11 claims
- 0788US9828358B2Compositions comprising an inhibitor of lysine specific demethylase-1CELGENE QUANTICEL RES INC·Filed 2016·Granted Nov 28, 2017·5 cites·20 claims
- 0888US9403829B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2012·Granted Aug 2, 2016·13 cites·29 claims
- 0984US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 1080US10047090B2Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Aug 14, 2018·3 cites·4 claims
- 1175US9303014B2Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2015·Granted Apr 5, 2016·1 cites·3 claims
- 1274US9266858B2Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2015·Granted Feb 23, 2016·1 cites·24 claims
- 1371US9604939B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2014·Granted Mar 28, 2017·1 cites·10 claims
- 1464US9827243B2Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-oneSIGNAL PHARM LLC·Filed 2016·Granted Nov 28, 2017·0 cites·17 claims
- 1559US9974786B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted May 22, 2018·0 cites·18 claims
- 1658US9795603B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Oct 24, 2017·0 cites·18 claims
- 1754US10513519B2Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their useSIGNAL PHARM LLC·Filed 2018·Granted Dec 24, 2019·0 cites·30 claims
- 1842US10590136B2Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2018·Granted Mar 17, 2020·0 cites·21 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →